SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.

TitleSRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.
Publication TypeJournal Article
Year of Publication2004
AuthorsBermudez LE, Kolonoski P, Seitz LE, Petrofsky M, Reynolds R, Wu M, Young LS
JournalAntimicrobial agents and chemotherapy
Volume48
Issue9
Pagination3556-8
Date Published2004 Sep
ISSN0066-4804
KeywordsAnimals, Anti-Bacterial Agents, Aza Compounds, Colony Count, Microbial, Drug Interactions, Drug Therapy, Combination, Female, Liver, Mefloquine, Mice, Mice, Inbred C57BL, Mycobacterium avium-intracellulare Infection, Quinolines, Spleen, Thioacetazone
Abstract

Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone.

DOI10.1128/AAC.48.9.3556-3558.2004
Alternate JournalAntimicrob. Agents Chemother.